Enterprise Bank & Trust Co Sells 61 Shares of Danaher Co. (NYSE:DHR)

Enterprise Bank & Trust Co lowered its stake in Danaher Co. (NYSE:DHR) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,208 shares of the conglomerate’s stock after selling 61 shares during the quarter. Enterprise Bank & Trust Co’s holdings in Danaher were worth $2,560,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of DHR. Tsfg LLC lifted its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Danaher during the second quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the second quarter worth about $25,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher in the 1st quarter valued at approximately $30,000. Finally, Richardson Financial Services Inc. bought a new stake in Danaher in the 4th quarter valued at approximately $42,000. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.1 %

Shares of DHR opened at $269.09 on Thursday. The firm has a market cap of $199.31 billion, a P/E ratio of 45.61, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The firm’s 50-day simple moving average is $270.89 and its 200 day simple moving average is $258.85.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.05 earnings per share. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s payout ratio is presently 18.31%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DHR. Bank of America raised their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Robert W. Baird increased their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Stephens started coverage on Danaher in a research report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.